Galectin Therapeutics Inc’s filing revealed that its Director Shlevin Harold H. acquired Company’s shares for reported $7540.0 on Dec 30 ’24. In the deal valued at $1.16 per share,6,500 shares were bought. As a result of this transaction, Shlevin Harold H. now holds 15,206 shares worth roughly $36342.340000000004.
Then, Jamil Khurram sold 13,654 shares, generating $12,044 in total proceeds. Upon selling the shares at $0.88, the Chief Medical Officer now owns 26,346 shares.
Before that, LEWIS JOEL sold 56,000 shares. Galectin Therapeutics Inc shares valued at $49,610 were divested by the President and CEO at a price of $0.89 per share. As a result of the transaction, LEWIS JOEL now holds 897,012 shares, worth roughly $2.14 million.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid August has reiterated a ‘”a Buy”‘ rating for it. B. Riley FBR began covering GALT with “Buy” recommendation on February 13, 2019. H.C. Wainwright maintained its rating on December 07, 2017. It rated GALT as “a Buy”.
Price Performance Review of GALT
On Tuesday, Galectin Therapeutics Inc [NASDAQ:GALT] saw its stock jump 60.40% to $2.39. Over the last five days, the stock has gained 78.36%. Galectin Therapeutics Inc shares have risen nearly 85.27% since the year began. Nevertheless, the stocks have fallen -10.15% over the past one year. While a 52-week high of $3.17 was reached on 06/17/25, a 52-week low of $0.73 was recorded on 01/14/25.
Levels Of Support And Resistance For GALT Stock
The 24-hour chart illustrates a support level at 1.6900, which if violated will result in even more drops to 0.9900. On the upside, there is a resistance level at 2.9400. A further resistance level may holdings at 3.4900.
The most recent change occurred on November 28, 2017 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $6.
